MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention

MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention

Abstract Background Erenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab before official reimbursement. The Spanish Neurological Society start...

Full description

Bibliographic Details
Main Authors: Robert Belvís, Pablo Irimia, Patricia Pozo-Rosich, Carmen González-Oria, Antonio Cano, Javier Viguera, Belén Sánchez, Francisco Molina, Isabel Beltrán, Agustín Oterino, Elisa Cuadrado, Angel Gómez-Camello, Miguel Alberte-Woodward, Carmen Jurado, Teresa Oms, David Ezpeleta, Javier Díaz de Terán, Noemí Morollón, Germán Latorre, Marta Torres-Ferrús, Alicia Alpuente, Raquel Lamas, Carlos Toledano, Rogelio Leira, Sonia Santos, Margarita Sánchez del Río
Format: Article
Language:English
Published: BMC 2021-07-01
Series:The Journal of Headache and Pain
Subjects:
Erenumab
Migraine
Monoclonal antibody
Preventive treatment
Registry
Online Access:https://doi.org/10.1186/s10194-021-01267-x

Internet

https://doi.org/10.1186/s10194-021-01267-x

Similar Items